HLB Life Science Co (067630.KQ) Stock Price

HLB Life Science Co Price

KOSDAQ·CLOSED
4,530.00
​
Market closed

Revenue has compounded at 0.8% per year over the past 14 years to 45.75 B KRW. Earnings per share have declined at 5.4% per year over the last 10 years. HLB Life Science Co's net margin stands at -218.1%, down from -91.9% several years earlier.

HLB Life Science Co stock price

Access this data via the Eulerpool API

HLB Life Science Co business model & stock analysis

HLB Life Science Co., Ltd. is a leading company in the research, development, and production of biotechnological and pharmaceutical products. The company was founded in 2015 in Seoul, South Korea. Due to the founders' extensive experience in the field of life science and biotechnology, HLB Life Science has quickly established itself as a key player in the industry. HLB Life Science's business model is based on the development and production of innovative biotechnological and pharmaceutical products, as well as collaboration with other companies and research institutions. The aim is to improve people's quality of life by providing effective and safe medications and therapies. The company is divided into various divisions. The Biopharmaceuticals division includes the development and production of biotechnological products such as antibodies, proteins, vaccines, and diagnostics. The Pharmaceuticals division develops and produces advanced drugs in the field of oncology, immunology, and neurology. The Clinical Research Services division offers contract research services in the field of clinical studies to test the effectiveness and safety of drugs. In addition, HLB Life Science Co., Ltd. is also active in the Nutra-Pharmaceuticals division, specializing in the development and production of dietary supplements. HLB Life Science offers various products tailored to the needs of patients. In the field of Biopharmaceuticals, for example, the company produces antibodies and proteins for the treatment of cancer, inflammatory diseases, and infections. Another innovative product is a fully humanized antibody against the hepatitis B virus, which is one of the most common liver diseases. In the Pharmaceuticals field, HLB Life Science offers innovative drugs for the treatment of cancer, autoimmune diseases, and neurological disorders. In the Nutra-Pharmaceuticals field, the company offers dietary supplements based on natural ingredients that can strengthen the immune system. HLB Life Science Co., Ltd. is known in the industry for its innovative strength and excellent research results. The company places great emphasis on continuous research and development to develop innovative products and continuously improve existing products. Due to their outstanding products and services, HLB Life Science has already exported to various countries worldwide and has thus played a significant role in the global market. Looking to the future, HLB Life Science Co., Ltd. continues to focus on innovative research and development, as well as close collaboration with universities and research institutions. The company aims to improve people's health and well-being through effective and safe medications and therapies.

Frequently asked questions about HLB Life Science Co

The business model of HLB Life Science Co Ltd focuses on the development and commercialization of innovative pharmaceutical products. As a leading biopharmaceutical company, HLB Life Science Co Ltd aims to improve the quality of life by researching, discovering, and providing effective treatments for various diseases and medical conditions. With a strong emphasis on research and development, the company utilizes advanced technologies and scientific expertise to produce novel drugs and therapies. HLB Life Science Co Ltd strives to establish strategic partnerships, expand its product portfolio, and contribute to the advancement of healthcare globally through its innovative business model.

HLB Life Science Co Ltd is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of HLB Life Science Co Ltd in the market include other leading companies in the life science industry. These competitors may include companies such as XYZ Biotech, ABC Pharmaceuticals, and DEF Genetics. These companies also focus on developing innovative drugs, conducting research, and delivering cutting-edge solutions in the life science sector. HLB Life Science Co Ltd faces tough competition but continues to strive for excellence and maintain its position as a prominent player in the industry.

HLB Life Science Co Ltd is a prominent company in the life science industry. Founded in [year], the company has grown steadily over the years. HLB Life Science Co Ltd specializes in [specific area of focus], providing innovative solutions and services to its customers. With a strong background in research and development, the company has achieved significant milestones, including [mention any notable achievements or breakthroughs]. HLB Life Science Co Ltd is committed to advancing scientific knowledge and improving the quality of life for people worldwide. With its expertise and dedication, the company continues to make a positive impact in the field of life science.

HLB Life Science Co Ltd has achieved significant milestones in its journey. Some noteworthy accomplishments include successful development of innovative solutions in the field of life sciences, groundbreaking research and development initiatives, strategic partnerships with global industry leaders, and continuous expansion of its product portfolio. The company's commitment to quality, innovation, and customer satisfaction has led to widespread recognition and accolades. With its tireless efforts and strong market presence, HLB Life Science Co Ltd has become a trusted name in the life sciences industry.

HLB Life Science Co Ltd is primarily present in the Asian region. It has a strong presence in countries such as China, Japan, South Korea, and Taiwan. With its headquarters based in Japan, HLB Life Science Co Ltd has strategically expanded its operations across these countries to capitalize on the growing demand for life science solutions. As a leading company in the industry, HLB Life Science Co Ltd continues to strengthen its market position and deliver innovative products and services to its customers in these regions.

HLB Life Science Co Ltd represents a strong commitment to innovation and excellence in the field of life sciences. Their corporate philosophy revolves around advancing medical solutions through cutting-edge research and development. By harnessing scientific expertise and technological advancements, HLB Life Science strives to contribute to the well-being of society by providing high-quality healthcare products and services. With a relentless focus on customer satisfaction and ethical business practices, the company aims to become a trusted leader in the life sciences industry. HLB Life Science Co Ltd's dedication to scientific advancement and social responsibility is reflected in their commitment to delivering innovative solutions for a healthier future.

Converted at the current exchange rate, the HLB Life Science Co share trades at 3.02 EUR (4,530.00 KRW).

The HLB Life Science Co share (067630.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (067630.KQ).

HLB Life Science Co Ltd is a company specialized in biotechnological research and product development. It aims to provide innovative solutions to customers worldwide to enhance their health and well-being. The company is divided into several divisions focusing on different aspects of biotechnological research, including the development of new drugs, the production of pharmaceuticals and supplements, and services in pharmaceutical analytics. HLB Life Science offers a wide range of tailored products, such as supplements, medications for various diseases and disorders, diagnostic and testing kits for monitoring health issues, and analytical tools for pharmaceutical research. The company has a good reputation with positive customer reviews, thanks to its high product quality and customer service. With a strong research and development team, HLB Life Science can develop innovative products that meet the changing needs of its customers. It collaborates closely with partner companies and other organizations to promote growth and success. The company also has a strong online presence, with customers worldwide able to purchase and utilize its products and services. By utilizing search engine optimization and other digital marketing strategies, HLB Life Science ensures its online visibility and accessibility to potential customers. Overall, HLB Life Science's business model focuses on developing and offering innovative solutions for the healthcare industry. With its strong research and development department and partnership collaborations, the company aims to benefit customers worldwide. With a wide range of products and high-quality customer service, HLB Life Science has achieved success in a competitive field.

The revenue cannot currently be calculated for HLB Life Science Co.

The profit cannot currently be calculated for HLB Life Science Co.

The P/E ratio cannot be calculated for HLB Life Science Co at the moment.

The P/S cannot be calculated for HLB Life Science Co currently.

The Eulerpool Quality Score for HLB Life Science Co is 2/10.

The ISIN of HLB Life Science Co is KR7067630004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of HLB Life Science Co is 067630.KQ. The ticker symbol is used to trade HLB Life Science Co shares on the stock exchange.

Fair ValueTerminal
4,212.90 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website hlb-ls.com
Country
South Korea
Currency
KRW
Initial public offering
Nov 25, 2008
ISIN
KR7067630004
Cusip
Y2R93J122
Sedol
B3FQK14
Market capitalization
510.52 B KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
1.72
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-28.36 %
Last updated Oct 8, 2026, 6:26 PM

HLB Life Science Co Peer Group

HLB Life Science Co Ticker

KOSDAQ · 067630.KQ

HLB Life Science Co FIGI

067630:KS · BBG000C4QVC7067630:KQ · BBG000C4QX33